Response to Commentary on “Impact of Disease‐Specific Treatment and NSBBs on Risk of PVT in Cirrhotic Patients With HCV or PBC ”

Humberto C. González; Stuart C. Gordon; Sheri Trudeau; Trueman Wu; Loralee B. Rupp; Christina Melkonian; Mark A. Schmidt; Yihe G. Daida; Amandeep Sahota; Christopher L. Bowlus; Mei Lü

doi:10.1111/liv.70839

August 12, 2026Liver International

Response to Commentary on “Impact of Disease‐Specific Treatment and NSBBs on Risk of PVT in Cirrhotic Patients With HCV or PBC ”

View Full Paper

Ask AI

Bookmark

Share

Key Points

Address commentary and clarify findings regarding the impact of disease-specific therapies and non-selective beta-blockers on portal vein thrombosis risk in cirrhotic liver disease.
Author correspondence responding to scientific commentary on prior cohort data.
Data availability stated as accessible from the corresponding author upon reasonable request.
Original study data and responses supporting the findings remain available upon direct request.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Author correspondence clarifies treatment and beta-blocker effects on portal vein thrombosis risk in cirrhotic patients, highlighting clinical management strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

González et al. (2026) studied this question.

synapsesocial.com/papers/6a7ec71db70b84ec8b9133fe https://doi.org/10.1111/liv.70839

View Full Paper

Ask AI

Bookmark

Share

Response to Commentary on “Impact of Disease‐Specific Treatment and NSBBs on Risk of PVT in Cirrhotic Patients With HCV or PBC ”

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Response to Commentary on “Impact of Disease‐Specific Treatment and NSBBs on Risk of PVT in Cirrhotic Patients With HCV or PBC ”

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading